At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
Quinacrine +1 moredrug
Likely dose
Quinacrine 100 mg orally three times dailyAI-extracted
Key inclusion· 5
- ✓Diagnosis of probable sCJD (progressive dementia with typical EEG or MRI plus ≥2 clinical features: myoclonus, pyramidal/extrapyramidal signs, visual symptoms, cerebellar signs, akinetic mutism, or focal cortical signs) or definite sCJD (biopsy-confirmed)
- ✓Age 18 years or older
- ✓Able to swallow
- ✓Able to follow simple one-step commands
Key exclusion· 12
- ✕History of cancer, end-stage liver or renal disease, or severe heart disease
- ✕Liver disease
- ✕Active alcoholism
- ✕Bone marrow suppression
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease
In Brief
A Phase 2 clinical trial evaluating Quinacrine and Placebo for Creutzfeldt-Jakob Disease. Completed, enrolled 69 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCreutzfeldt-Jakob Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2005
First PostedSep 2005
Primary CompletionJun 2012
TodayJul 2026
First PostedSep 16, 2005
Enrollment StartApr 1, 2005
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 20.8 years ago
Interventions
Quinacrinedrug
100mg by mouth three times a day
Placebodrug
100mg by mouth three times a day